

Z chirurgických metod využívaných při HS sa v literatúre uvádza deroofing, t.j. odstránenie kožného krytu fistúl a abscesov s následným hojením per secundam. Ďalej je to excízia skalpelom, elektrochirurgicky alebo pomocou CO₂ lasera, excízia šetriaca kožu v kombinácii s elektrochirurgickým pelengom a fototermolýza folikulárnej jednotky Nd:YAG

laserom (3). Niekedy je radikálny chirurgický výkon jedinou kurabilnou metódou (2).

Záver

Niektoré zdroje uvádzajú ako priemernú dobu správnej diagnostiky pacienta s HS 7,5 roka. Práve včasná diagnostika a liečba v počiatočných prejavoch je kľúčová z hľadiska

kontroly zápalovej aktivity ochorenia a ďalšej prognózy. Dôsledný monitoring komorbidít a komplikácií HS, ktoré vychádzajú zo samotného ochorenia, ale aj jeho liečby, môže byť rozhodujúci pre kvalitu života pacienta s týmto vyčerpávajúcim ochorením. U všetkých pacientov s pokročilým ochorením je potrebný multidisciplinárny prístup.

LITERATÚRA

- Péčová K. Hidradenitis suppurativa – biologická liečba. Dermatol.prax. 2016;10(4):126-129.
- Urbanček S, Vorčáková K. Aktuálna farmakoterapia Hidradenitis suppurativa. Dermatol.prax. 2022;16(1):14-16.
- Vorčáková K, Péčová K, Madleňák M, et al. Hidradenitis suppurativa – terapeutická výzva pre dermatológa. Dermatol. Prax. 2021;15(2):62-67.
- Van der Zee HH, Riuter L, Broecke DG, et al. Elevated levels of tumor necrosis factor alfa, interleukin 1 beta in hidradenitis suppurativa skin: a rationale for targeting TNF alfa and IL beta. Brit jour. of Derm. 2011;164:1292-1298.
- Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5)(suppl 1):S8-S11. doi:10.1016/j.jaad.2015.07.045.
- Revuz JE, Canoui-Poitine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies. J Am Acad Dermatol. 2008;59:596-601.
- Walter A, Meissner M, Kaufmann R et al. Hidradenitis Suppurativa after radical surgery – long term follow up for recurrences and associated factors. Dermatol Surg. 2018;44(10):1323-1331.
- Alikhan A, Sayed C, Alavi A, et al. Original Articles North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Dermatology. 2019;81:76-90.
- Garag A, Neuren E, Strunk A. Hidradenitis suppurativa Is Associated with Polycystic Ovary Syndrome: A Population-Based Analysis in the United States. Journal of Investigative Dermatology. 2018;138:1288-1292.
- Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradeni-

- tis suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434-1442.
- Sevray M, Dupre PF, Le Flaheac G, et al. Vulvar squamous cell carcinoma complicating hidradenitis suppurativa in a young woman. JAAD Case Reports. 2019;5:999-1001.
- Schmitz L, et al. Histologic classification of cutaneous squamous cell carcinomas with different severity. J Eur Acad Dermatol Veereol. 2019;8:11-15. doi: 10.1111/jdv.15950.
- Ivanková B, Baloghová J. Nežiadúce kožné prejavy onkologickej liečby. Čes. Dermatovenerol. 2022;12(1):25-29.
- Poláková K, Murárová Z. Štandardné postupy. Manažment nemelanómovej rakoviny kože. Rakovina z keratinocytov. Manažment kožného skvamocelulárneho karcinómu. MZ SR; 2021.
- Passarelli A, Mannavola F, Stucci LS, et al. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8(62):106132-106142.
- Cohen-Kurzock PR, et al. Cutaneous Metastatic Breast Cancer Masked by Hidradenitis suppurativa. Cureus 2021;13(1):e12862. doi: 10.7759/cureus.12862.
- Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J. Eur. Acad Dermatology venereol. 2015;29:619-644.
- Machado MO, et al. Depression and Anxiety in Adults With Hidradenitis Suppurativa, A Systemic Review and Meta-analysis. JAMA Dermatol. 2019;155(8):939-945.
- Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82:366-376.
- Savage KT, Singh V, Patel ZS, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85(1):187-199.
- Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, et al. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2021;12:1-34.
- Kerdel FR, Azevedo FA, Kerdel Don C, et al. Apremilast for the treatment of mild to moderate hidradenitis suppurativa in a prospective, open – label, phase 2 study. J Drugs Dermatol. 2019;18(2):170-176.
- Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with Rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford). 2005;44(2):157-163.
- Micic D, Kamaki Y, Alavanja A, et al. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019;53(1):e1-e11. doi:10.1097/MCG.0000000000000865.
- Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
- Pellegrini Ch, Esposito M, Rossi E, et al. Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. Dermatol Ther. 2022;12:2613-2626.
- Tannenbaum R, Strunk A, Garg A. Association Between Hidradenitis suppurativa and Lymphoma. JAMA Dermatol. 2019;155(5):624-625.
- Stratigos A, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. European Journal of Cancer. 2020;128(83-102).

MĚJTE SE V NOVÉM
ROCE TAK HEZKY JAKO
NAŠI MAZLIČCI

 SOLEN

PF 2024

